00 Hardcover Infectious disease RC606 Nucleoside analog reverse transcriptase inhibitors (NRTIs), the first antiretroviral agents to be introduced to the market back in 1987, remain a mainstay of anti-HIV therapy.
What does NARTI stand for?
NARTI stands for Nucleoside Analog Reverse Transcriptase Inhibitor (AIDS treatment)
This definition appears somewhat frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of NARTI
We have 2 other meanings of NARTI in our Acronym Attic
- Native American Research and Training Center (University of Arizona; Tucson, AZ)
- Naval Air Research Training Command (US Navy)
- North American Regional Test Center
- Non Alcoholic Ready to Drink
- National Association of Radio and Telecommunications Engineers
- National Association of Radio and Television Engineers
- National Association of Radio and Telecommunication Engineers
- National Association for Research and Therapy of Homosexuality
- National Association for Research and Treatment of Homosexuality (now National Association for Research and Therapy of Homosexuality; est. 1992)
- Northwest Arkansas Radiation Therapy Institute
- National Association of Road Transport Modellers (est. 1983; UK)
- National Association of Road Transport Museums (UK)
- National Association of Road Transport Owners (Nigeria)
- Nigerian Association of Road Transport Owners
- National Alliance of Respiratory Therapy Regulatory Bodies (Canada)
- National Association of Resale and Thrift Shops
- National Association of Rocketry Technical Services
- Naval Air Rocket Test Station (Lake Denmark, Dover, NJ)
- National Association of Radio Talk Show Hosts
- Naval Air Reserve Training Unit
Samples in periodicals archive:
Reverset was effective in patients with HIV resistant to other commonly used nucleoside analog reverse transcriptase inhibitors, including the two-thirds of patients with the M41L multiple thymidine analog mutation, Dr.
About Reverset Reverset is a nucleoside analog reverse transcriptase inhibitor that is being developed as a once-daily oral HIV therapy by Incyte Corporation and Pharmasset, Inc.
The program makes PREVEON available free of charge to HIV infected adults in the United States who have failed treatment with at least two nucleoside analog reverse transcriptase inhibitors and one protease inhibitor.
Program Design -- The program will make PREVEON available free of charge to HIV-positive patients at least 13 years of age who have failed treatment with at least two nucleoside analog reverse transcriptase inhibitors and one protease inhibitor, and who have had, within the past two months, a CD4 count less than or equal to 50 cells/mm3 and an HIV RNA level of greater than or equal to 30,000 copies/mL by PCR.